Steve Landau, MD
Dr. Landau serves as a Consultant Chief of Development for Heranova. He is most prominently consulting for Companies in the medical area.
He serves (part-time) as Chief Medical Officer for GV20 Therapeutics. He was employed part-time as Chief of Clinical Development at Hangzhou Just Biochina (HJB) between 2017 and 2019, a leading biologics firm specializing in the research and development of leading antibodies. He is a Senior Consultant to Ocumension, a leading Ophthalmic Company in China.
Dr. Landau is a summa cum laude graduate of Bowdoin College and a member of Phi Beta Kappa. He earned his M.D. from Case Western Reserve University in Cleveland, Ohio, graduating as a member of Alpha Omega Alpha. Dr. Landau completed his post-graduate training at the Beth Israel Hospital in Medicine and the Brigham and Women’s Hospital in Gastroenterology, both in Boston.
Dr. Landau has been in the biotechnology field for approximately 25 years. He was the Founder and a Consulting Chief of Development for Convelo Therapeutics, focused on re-myelination. He has been associated with OraVax, LeukoSite, Inc., Millennium Pharmaceuticals, Inc., (by merger), Praecis Pharmaceuticals, Inc., Dynogen Pharmaceuticals Inc, Shape Pharmaceuticals, and Tensha Therapeutics. At LeukoSite, he was responsible for initial clinical trials in the area of Inflammatory Bowel Disease, with subsequent worldwide approval of the study drug. At Praecis, he was responsible for successfully completing a clinical study in patients with endometriosis using an early GNRH antagonist. Dr. Landau was at Dynogen Pharmaceuticals with a focus on urologic disease, where he was initially the vice president of clinical development and subsequently was appointed senior vice president of strategic corporate development. For 10 years, he was associated with a venture capital group in Boston.